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Abstract
Mutations in the transient receptor potential vanilloid 4 (TRPV4) gene have been associated with autosomal dominant skeletal dysplasias and
peripheral nervous system syndromes (PNSS). PNSS include Charcot–Marie–Tooth disease (CMT) type 2C, congenital spinalmuscular atrophy and
arthrogryposis and scapuloperoneal spinalmuscular atrophy.We report the clinical, electrophysiological andmuscle biopsy findings in two unrelated
patients with two novel heterozygous missense mutations in the TRPV4 gene. Whole exome sequencing was carried out on genomic DNA using
IlluminaTruseqTM 62Mbexome capture. Patient 1 harbours a de novo c.805C > T (p.Arg269Cys)mutation.Clinically, this patient shows signs of both
scapuloperoneal spinal muscular atrophy and skeletal dysplasia. Patient 2 harbours a novel c.184G > A (p.Asp62Asn) mutation. While the clinical
phenotype is compatible with CMT type 2C with the patient’s muscle harbours basophilic inclusions. Mutations in the TRPV4 gene have a broad
phenotypic variability and disease severity and may share a similar pathogenic mechanism with Heat Shock Protein related neuropathies.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/
4.0/).
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1. Introduction
TRPV4 (transient receptor potential vanilloid 4 channel;
OMIM 605427) is a calcium permeable non-selective cation
channel expressed in several tissues and cell types [1]. In bone
it is expressed in osteoblasts, osteoclasts and chondrocytes and
may be involved in bone remodelling. In the peripheral nervous
system TRPV4 expression was demonstrated in the skin
sensory receptors, in the dorsal root ganglia and to a lesser
extent in the motor neurons [2]. The precise role of TRPV4 in
neurons has not yet been fully elucidated. TRPV4 is also
expressed in smooth muscle cells [1] and in mouse skeletal
muscle [3].
The TRPV4 gene (NM_021625.4) is located on chromosome
12q23-q24.1 and is composed of 15 exons coding 5 different
splice variants. Only 2 of the splice variants, TRPV4A and
TRPV4D, are processed by the endoplasmic reticulum and
incorporated into the plasma membrane [1]. The longest
isoform (isoform a) of TRPV4 comprises 871 amino acids and
has 2 intracellular domains, namely the N- and C-termini, and
six transmembrane alpha–helix domains. The N-terminus is
composed of six ankyrin repeats and the C-terminus consists of
several calmodulin binding sites [4,5].
Dominant mutations in TRPV4 have been described in both
peripheral nervous system and skeletal diseases. PNSS
include hereditary motor and sensory neuropathy type
2C or Charcot–Marie–Tooth disease type 2C (HMSN2C
or CMT2C; OMIM 606071), congenital spinal muscular
atrophy and arthrogryposis (CSMAA; OMIM 600175) and
scapuloperoneal spinal muscular atrophy (SPSMA; OMIM
181405). Vocal cord paralysis and sensorineural hearing
deficit were frequently associated findings in patients with
neuropathies. Among the skeletal dysplasias, TRPV4
mutations have been described in patients with brachyolmia
(OMIM 113500), spondylometaphyseal dysplasia Kozlowski
type (SMD-K; OMIM 184252), metatropic dysplasia
(OMIM 156530), parastremmatic dysplasia (OMIM 168400),
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and spondyloepimetaphyseal dysplasia Maroteaux type
(SEMD-M; OMIM 184095). There are only a few patients
reported with the combination of peripheral neuropathy and
skeletal dysplasia [6,7]. A few muscle pathology descriptions
in TRPV4-related neuropathies point towards a chronic
neurogenic process without any specific or distinguishable
features [7].
Here we report two patients, one manifesting a combination
of scapuloperoneal spinal muscular atrophy and skeletal
dysplasia while the other presented with a CMT2C phenotype
and basophilic inclusions in the muscle biopsy.
2. Patients and methods
2.1. Patients
2.1.1. Patient 1
This 8-year-old boy is the second child of non-consanguineous
parents. He was born at 36 weeks gestation by caesarean section
due to pre-eclampsia. His birth weight was 2.64 kg and theApgar
score was normal. There is no family history of a neuromuscular
condition. His mother is healthy while his father suffers from
ankylosing spondylitis. At the age of 10 weeks he was diagnosed
with a torticollis and noted to be a floppy baby with difficulties in
moving his legs and his left arm. Due to delayed motor
development he was able to sit only at the age of 8 months and he
walked at the ageof 22months.Hehad amild expressive language
delay; being unable to pronounce clear words by the aged of 24
months. He was first seen at the age of 30 months due to unsteady
gait, inability to jump or run and frequent falls. There were minor
swallowing problems both with solids and liquids.
There was a slight lumbar lordosis, short stature, short lower
limbs, brachydactyly, flat feet and genus valgus, suggestive of
skeletal dysplasia. Physical examination (Fig. 1) revealed intact
cranial nerves. The eye movements and hearing were normal;
there was no tongue fasciculation or facial weakness. Proximal
and distal lower limb weakness and proximal upper limb
weakness were noted bilaterally. Muscle wasting was present in
the lower limbs with a more pronounced effect on the distal
muscle groups. There was mild scapular winging, marked
waddling gait, bilateral foot drop and a positive partial Gower’s
manoeuvre. Deep tendon reflexes were absent in the lower
limbs. There were no sensory changes, signs of tremor, ataxia,
dystonia or joint hyperlaxity.
Laboratory investigations including serum CK level were
unremarkable. Spinal cord MRI scan did not show any
abnormalities. Motor and sensory nerve conduction velocities
of the lower limbs were normal. Needle electromyography
revealed a chronic neurogenic pattern with minimal active
denervation. Video fluoroscopy showed weak oral stage with
poor bolus control. There was no respiratory or cardiac
involvement. Genetic analysis did not detect mutations in
SMN1, IGHMBP2, MFN2 or FSHD1 genes.
2.1.2. Patient 2
Patient 2 is a 48-year-old female, who had normal motor
development and motor function until the age of 40 years. There
Fig. 1. (a) Picture of patient 1 showing the disproportion between the size of the trunk and legs, short stature, short lower limbs, brachydactyly, flat feet and genus
valgus. (b) Muscle biopsy (H&E) showing increased variation in fibre size with both scattered and small groups of atrophic fibres.
(c) Muscle biopsy (ATPase 4.3) revealing type 1 fibre predominance and a tendency for type-grouping.
517T. Evangelista et al. /Neuromuscular Disorders 25 (2015) 516–521
was no family history of a neuromuscular condition, but her
younger brother was born with bilateral talipes. He was unable
to attend our clinic for neurological and electrophysiological
examinations. The first symptom of patient 2 was recurrent
twisting of the right ankle, which occurred by the age of 40
years. There were progressive walking difficulties, due to lower
limb weakness. There were no cardiac or respiratory
manifestations.
On physical examination cranial nerves were normal.
Bilateral foot drop, steppage gait and weakness of the lower
limbs were observed. In the proximal segments the strength was
grade 4/5 and in the distal ones grade 2/5 according to Medical
Research Council Scale for muscle strength. Deep tendon
reflexes were normal except for the patella reflexes which were
pathologically brisk. The plantar reflex response was flexor.
There was minor pinprick and vibration sensory loss in the toes.
Muscle tone and bulk were normal.
Laboratory tests including serumCK levelwere unremarkable.
Brain and spinal cordMRI scans did not show any lesions. Motor
and sensory nerve conduction velocities of the lower limbs were
normal, but reduced motor amplitudes in the right peroneal
(1.8 mV) and right tibial (5 mV) and absent F-waves were
observed. Upper limb motor studies were normal but the
amplitude of sensory potential in the right sural nerve was
reduced. Needle electromyography revealed minimal active
denervation and chronic neurogenic changes with occasional
fibrillation potentials. Muscle MRI (Fig. 2) showed, on
T1-weighted axial images, symmetrical atrophy and fat
infiltrationof the gluteus, hamstrings and calfmuscles.Diagnostic
genetic testing did not identify mutations in SMN1, HSPB1 and
HSPB8 genes.
2.2. Methods
2.2.1. Muscle biopsy
Both patients underwent open muscle biopsy from the left
quadriceps for patient 1 and left tibialis anterior for patient 2.
The biopsies were processed according to standard methods [8].
2.2.2. Genetic analysis
Whole-exome sequencing was carried out in both patients
using genomic DNA extracted from peripheral blood
lymphocytes, fragmented, and exome enriched by Illumina
TruSeq™ 62 Mb and sequenced on a HiSeq 2000 with 100 bp
paired-end reads. Bioinformatic analysis was performed using
an in-house algorithm based on published tools. The sequence
was aligned to the human reference genome (UCSC hg19)
using Burrows–Wheeler Aligner and reformatted using
SAMtools. Duplicated sequence reads were removed (Picard
v.185) and variants were identified using VarScan (v.2.2) and
Dindel (v1.01).
Results were further filtered for variants with a minor allele
frequency less than 0.01 in several databases: dbSNP135, 1000
genomes (February 2012 data release), the National Heart,
Lung and Blood Institute (NHLBI, NIH, Bethesda, MD)
Exome Sequencing Project (ESP) 6500 exomes, and 238
unrelated in-house controls, in order to detect rare variants. We
selected candidate variants among known neuropathy-related
disease genes [9].
Patient 2 was tested in parallel for a panel of 56 genes
associated with inherited peripheral neuropathies, usingAgilent
SureSelectXT2 custom target enrichment system and Next
Generation Sequencing. We carried out PCR (IMMOLASE™
DNA Polymerase, Bioline UK) and Sanger sequencing
(BigDye®Terminator v3.1) of variants which were predicted to
be deleterious by three online prediction tools (MutationTaster,
SIFT and Polyphen2).
3. Results
3.1. Muscle histology
In patient 1 (Fig. 1) muscle biopsy showed increased
variation in fibre size with both scattered and small groups of
atrophic fibres. ATPase stain showed type I fibre predominance
with many of the fascicules being entirely type I. In some
fascicules there were areas of fibre type grouping, indicative of
a chronic neuropathy.
In patient 2 (Fig. 3) there was evidence of neurogenic
atrophy, increased muscle fibre size variation with both
hypertrophic and atrophic fibres. The atrophic fibres occurred
in clusters and some were angulated. There was a tendency to
fibre type grouping and an increase in the number of internal
Fig. 2. Muscle MRI, T1-weighted axial images, symmetrical atrophy and fat
infiltration of the gluteus, hamstrings and calf muscles.
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nuclei. Large, mainly central accumulation of basophilic
material was observed in occasional fibres (Fig. 3).
3.2. Genetic analysis
Patient 1 had a de novo, heterozygous missense mutation
c.805C > T (p.Arg269Cys) in exon 5 of the TRPV4 gene. This
mutation has been repeatedly reported in previous studies [10].
Both parents tested negative for this mutation. Patient 2 had a
novel heterozygous variant c.184G > A (p.Asp62Asn) in exon 2
of the TRPV4 gene. This novel variant was absent in the healthy
mother and was present in her brother, the father was deceased
and DNA was not available for testing. The sequence change is
predicted to cause the substitution of a moderately conserved
aspartic acid for an arginine at codon 62 in the N-terminal
cytoplasmic domain of the protein that contains six ankyrin
repeats. The theoretical prediction (SIFT, Polyphen 2 HDIV,
Polyphen 2 HVar, Mutation taster) based on in silico analysis
suggests that this variant may have a deleterious effect on the
protein function. This variant was not reported in dbSNP or the
ESP database, it has been seen once in 119,558 alleles
(http://exac.broadinstitute.org/variant/12-110252418-C-T), and
this rarity supports pathogenicity. No other potentially
deleterious variant was detected in any known myopathy or
neuropathy genes on whole exome sequencing.
4. Discussion
Here we report two patients with different clinical
presentations carrying pathogenic mutations in the TRPV4 gene.
Patient 1 has a phenotype combining scapuloperoneal spinal
muscular atrophy (SPSMA) and metatropic dysplasia. A similar
combination was reported previously in 3 patients [6] with
either spondylometaphyseal dysplasia Kozlowski type or
spondyloepimetaphyseal dysplasia Maroteaux type and HSMN
type II axonal neuropathy. Our patient has a clear clinical and
neurophysiological phenotype of SPSMA, supporting the
existence of combined skeletal muscle and nerve involvement.
Minor skeletal abnormalities in association with a neuropathy
were reported in some patients with TRPV4mutations previously
[7,11–13]. The mutation c.805C > T (p.Arg269Cys) was
described in patients with HSMN type IIC, with SPSMA and also
with distal congenital non progressive SMA [7,12,14–16],
suggesting significant clinical heterogeneity. To our knowledge
this mutation has never been associated with skeletal dysplasia;
however milder skeletal abnormalities may have been missed on
routine neurological examination.Our finding expands further the
clinical variability amongTRPV4mutations and highlight that the
presence of skeletal abnormalities in a patient with an axonal
neuropathy or neuronopathy should raise the possibility ofTRPV4
gene mutations.
Patient 2 presents with a phenotype compatible with CMT2C.
Although the mutation c.184G > A (p.Asp62Asn) has not been
previously reported, it was also present in the patient’s 29 year old
brother who had congenital bilateral talipes, but it was absent in
the asymptomatic mother. The in silico studies and mutation
prediction programmes indicate that this variant is probably
pathogenic by changing the conformation of the protein.
Fig. 3. (a) Picture of patient 2 shows the severe weakness in the feet. (b) Muscle biopsy from patient 2 showing neurogenic atrophy and large accumulations of
basophilic material.
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There are only a few reports on muscle histology in patients
with TRPV4 mutations. In most cases muscle pathology
demonstrated abnormalities consistent with chronic denervation
[7,17], such as in patient 1. These included increased variation in
fibre size with hypertrophic and scattered or small clusters of
atrophic muscle fibres and fibre type grouping, which could be
explainedby theneuropathy. Interestinglypatient 2 presentedwith
intra-cytoplasmic basophilic inclusions besides the neurogenic
changes. In vitro studies in HeLa cells showed that mutated
TRPV4 protein forms cytoplasmic aggregates without localizing
to the plasma membrane where wild-type TRPV4 proteins are
usually detected [10].
The accumulation and aggregation of misfolded proteins can
be highly cytotoxic and can lead to several neurodegenerative
conditions. Misfolded proteins tend to aggregate and precipitate
in the cells triggering different cytotoxic pathways. It is
hypothesized that aggregation of misfolded proteins and
formation of cytoplasmic aggregates are the main disease
pathways in neuropathies associated with mutations in the heat
shock protein genes (HSP) [18,19]. We speculate that TRPV4
mutations are associated with the production of misfolded
proteins, which can form cytoplasmic aggregates similar to
HSP related neuropathies. In support of this we emphasize the
fact that the muscle biopsy from patient 2 showed intracellular
aggregates, but the exact protein composition of these
aggregates has not been elucidated yet.
Muscle MRI of the thighs and calf muscles from patients
with SMA associated with TRPV4 mutations was reported
as having extensive fat atrophy with the preservation of
the biceps femoris and medial gastrocnemius [20]. In another
study in patients with TRPV4 mutations the adductors and
semitendinosus muscles were well preserved whereas the
quadriceps, vastus medialis, long head of biceps and
semimembranosus were abnormal. In the calves, the flexor
hallucis longus and peroneus brevis muscles were spared and
the gastrocnemius presented with a feather like atrophy [17]. In
patient 2 MRI showed symmetrical fat atrophy of the biceps
femoris, semitendinosus, semimembranosus and calf muscles.
At present, the reports on muscle MRI images of patients with
TRPV4 mutations do not show a characteristic pattern of
muscle involvement, most likely due to highly variable clinical
presentations. The detected changes are not typical for
a peripheral neuropathy affecting mainly distal groups. We
assume that the differences between our patient and the ones
reported byAstrea et al. [20] and Oates et al. [17] are due to the
fact that our case is a late onset form of the disease (CMT2C)
while the later ones corresponded to congenital forms of SMA.
Therefore muscle MRI is of limited benefit as a diagnostic tool
in TRPV4-related diseases.
5. Conclusions
In summary, mutations in the TRPV4 gene lead to a broad
spectrum of phenotypic manifestations withmarked variability in
disease severity. The association with skeletal deformities, in
particular short stature, brachydactyly, disproportion between the
lower and the upper halves of the body, may help with the
differential diagnosis. Vocal cord paralysis and, to a lesser extent,
neurosensory deafness are described as clinical clues to diagnose
TRPV4 associated neuropathies; however none of these were
present in our patients. The presence of intra-cytoplasmic
basophilic inclusions in muscle biopsies of patients with axonal
neuropathies should raise the possibility of mutations either in
TRPV4 or in heat shock protein genes.
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